The AAV2/Anc80L65 gene replacement therapy can potentially be adapted for conditions such as Usher syndrome, which is caused by mutations in genes like USH1C, leading to hearing loss, vestibular dysfunction, and retinitis pigmentosa. The gene discussed is USH1C; the disease is Usher syndrome.